Skip to main content
OpenTrials
Completed

NCT Number: NCT04754373

A Study to Evaluate the Effect of GFA-918 on Serum Triglyceride Levels in Individuals With Elevated Serum Triglyceride

In this study, a lipase -sourced from a nonpyrogenic yeast, Candida rugosa, will be investigated to establish optimal TG levels in adults in a 12-week supplementation period. The investigational product provides a lipase formulation that is stable and active in acidic and neutral pH environments, while also fully digesting TGs into free fatty acids and glycerol which is beyond the scope of pancreatic lipase (Schuler et al. 2012). This will be a novel study investigating the effects of C. rugosa lipase on adults with slightly elevated TG levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Elevated Triglycerides Dyslipidemias Hyperlipidemias Hypertriglyceridemia Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

KGK Science, London, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females and male within the age range of 30 to 70 at screening;
  • BMI of 20 - 34.9 kg/m2 at screening;
  • Not of child bearing potential, which is defined as females who have had hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR,

Female participants of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result, prior to enrollment. All hormonal birth controls require a minimum stability of three months and remain consistent throughout the study. Acceptable methods of birth control include:

  • Hormonal contraceptives; oral, hormone patch (Ortho Evra), vaginal ring (NuvaRing), injectable (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • Double-barrier method
  • Intrauterine devices
  • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
  • Vasectomy of partner (shown successful as per appropriate follow-up);
  • Sedentary life style as defined by Sedentary Behavior Questionnaire (Appendix II) at screening;
  • Serum triglycerides 1.91 - 3.93 mmol/L (175 - 350 mg/dL) (inclusive) at screening;
  • Willing to maintain current levels of activity throughout the study;
  • Stable with no health concerns for participating in the study as determined by laboratory results, and medical history;
  • Willingness to complete all study visits and requirements associated with the study;
  • Has access to a computer, tablet, or smart phone with internet connection;
  • Has given voluntary, written, informed consent to participate in the study.

Exclusion criteria

  • Individuals who are pregnant, breastfeeding, or planning to become pregnant;
  • LDL-C ≥ 4.1 mmol/L (160 mg/dL);
  • Uncontrolled hypertension, defined as untreated systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg;
  • Cancer(s), except skin cancers completely excised with no chemotherapy or radiation with a negative follow up. and cancer(s) in full remission for more than five years after diagnosis
  • Immunocompromised individuals such as those that have undergone organ transplantation, those with rheumatoid arthritis, or those diagnosed with human immunodeficiency virus (HIV) or AIDS by verbal confirmation;
  • Verbal confirmation of current, or history of, bleeding disorders and/or medically prescribed anticoagulant/antiplatelet drugs (refer to Section 5.3);
  • Verbal confirmation of current unstable thyroid disease state; however, participants who have been on stable medication for >6 months will be eligible to participate but will be assessed on a case by case basis by the QI.
  • Verbal confirmation of GI disorders and on anti-inflammatory drugs to control GI disorders; however, participants who have been on stable medication for >6 months will be eligible to participate but will be assessed on a case by case basis by the QI
  • Verbal confirmation of Type I and Type II Diabetes;
  • Anti-inflammatory medication, corticosteroids, lipid lowering agents and diabetic medication (refer to Section 5.3) as assessed by the QI;
  • Alcohol or drug abuse within the last 6 months;
  • No more than 2 standard alcoholic drinks per day;
  • Verbal confirmation of marijuana use >4 times a week
  • Tobacco products, including e-cigarette; dose and frequency will be assessed on a case by case basis by the QI
  • Participation in a clinical research study within 30 days of enrollment;
  • Allergy or sensitivity to study product ingredients;
  • Clinically significant abnormal laboratory results at screening;
  • Unstable medical conditions as assessed by the Qualified Investigator;
  • Individuals who are cognitively impaired and/or unable to give informed consent;
  • Any other condition which in the Qualified Investigator's opinion may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant.

Treatment and study plan

GFA-918

Dietary Supplement

Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.

Placebo

Other

Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.

Primary outcomes

  1. The change in levels of fasting serum TG levels

    Time frame: 12 weeks

    The primary outcome of this study is the change in levels of fasting serum TG levels from screening to week 12 in fasting serum TG levels between GFA-918 and placebo groups.

Secondary outcomes

  1. The change in levels of triglycerides

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (levels of triglycerides) between GFA-918 and placebo groups

  2. The change in levels of total cholesterol

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (levels of total cholesterol) between GFA-918 and placebo groups

  3. The change in levels of LDL-cholesterol

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile ( levels of LDL-cholesterol) between GFA-918 and placebo groups

  4. The change in levels of VLDL-cholesterol

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (levels of VLDL-cholesterol) between GFA-918 and placebo groups

  5. The change in levels of HDL-cholesterol

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (levels of HDL-cholesterol) between GFA-918 and placebo groups

  6. The change in levels of ApoA-I

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (levels of ApoA-I) between GFA-918 and placebo groups

  7. The change in levels of LDL-C: HDL-C

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (LDL-C: HDL-C) between GFA-918 and placebo groups

  8. The change in levels of TC: HDL-C

    Time frame: 12 weeks

    The change from baseline to week 12 in lipid profile (TC: HDL-C) between GFA-918 and placebo groups

  9. The change in levels of apolipoprotein A1 (ApoA-1)

    Time frame: 12 weeks

    The change from baseline to week 12 in apolipoprotein A1 (levels of ApoA-1) between GFA-918 and placebo groups.

  10. The change in levels of CRP

    Time frame: 12 weeks

    The change from baseline to week 12 in levels of the inflammatory biomarker, CRP, between the GFA-918 and placebo groups

  11. The change in levels of TNF-α

    Time frame: 12 weeks

    The change from baseline to week 12 in levels of the inflammatory biomarker, TNF-α, between the GFA-918 and placebo groups

  12. The change in levels of IL-6

    Time frame: 12 weeks

    The change from baseline to week 12 in levels of the inflammatory biomarker, IL-6, between the GFA-918 and placebo groups

  13. The change in body weight

    Time frame: 12 weeks

    The change from screening to week 12 in body weight between GFA-918 and placebo groups.

  14. The change in body mass index (BMI)

    Time frame: 12 weeks

    The change from screening to week 12 in body mass index (BMI) between the GFA-918 and placebo groups

  15. A clinically relevant change in TG after the 12-week supplementation with GFA-918 as assessed by a 1 mmol/L decrease in TG.

    Time frame: 12 weeks

    6A clinically relevant change in TG from screening to week 12 after the 12-week supplementation with GFA-918 as assessed by a 1 mmol/L decrease in TG.

  16. A clinically relevant change in HDL-C after supplementation with GFA-918 defined as at least 0.026 mmol/L (1 mg/dL) or 1% increase

    Time frame: 12 weeks

    A clinically relevant change in HDL-C, from baseline to week 12 after supplementation with GFA-918 defined as at least 0.026 mmol/L (1 mg/dL) or 1% increase

  17. The clinically relevant change in LDL-C after supplementation with GFA-918 defined as a minimal 1% decrease

    Time frame: 12 weeks

    The clinically relevant change in LDL-C, from baseline to week 12 after supplementation with GFA-918 defined as a minimal 1% decrease

  18. The changes during the follow up period, week 12 to week 14, in levels of fasting serum TG levels

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, in fasting serum TG levels between GFA-918 and placebo groups.

  19. The changes during the follow up period, week 12 to week 14, in complete lipid profile

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, complete lipid profile between GFA-918 and placebo groups.

  20. The changes during the follow up period, week 12 to week 14, in levels of ApoA-1

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, ApoA-1, between GFA-918 and placebo groups.

  21. The changes during the follow up period, week 12 to week 14, in levels of inflammatory biomarkers

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, inflammatory biomarkers, between GFA-918 and placebo groups.

  22. The changes during the follow up period, week 12 to week 14, in body weight

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, body weight between GFA-918 and placebo groups.

  23. The changes during the follow up period, week 12 to week 14, in BMI

    Time frame: 14 weeks

    The changes during the follow up period, week 12 to week 14, BMI, between GFA-918 and placebo groups.

  24. The clinical significant changes during the follow up period, week 12 to week 14, in levels of TG

    Time frame: 14 weeks

    The clinical significant changes during the follow up period, week 12 to week 14, in TG, between GFA-918 and placebo groups.

  25. The clinical significant changes during the follow up period, week 12 to week 14, in levels of HDL-C

    Time frame: 14 weeks

    The clinical significant changes during the follow up period, week 12 to week 14, in HDL-C, between GFA-918 and placebo groups.

  26. The clinical significant changes during the follow up period, week 12 to week 14, in levels of LDL-C

    Time frame: 14 weeks

    The clinical significant changes during the follow up period, week 12 to week 14, in LDL-C, between GFA-918 and placebo groups.

Other outcomes

  1. The incidence of adverse events with GFA-918.

    Time frame: 12 weeks

    The incidence of adverse events during the 12-week supplementation with GFA-918.

  2. The incidence of any abnormal vital signs: blood pressure (BP) and heart rate (HR), with GFA-918

    Time frame: 12 weeks

    The incidence of any abnormal vital signs: blood pressure (BP) and heart rate (HR), during the 12-week supplementation with GFA-918

  3. The incidence of any abnormal ECG with GFA-918

    Time frame: 12 weeks

    The incidence of any abnormal ECG during the 12-week supplementation with GFA-918

  4. The incidence of any abnormal hematology (white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils; during the 12-week supplementation with GFA-918.

  5. The incidence of any abnormal hematology; red blood cell (RBC) count, with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; hemoglobin, during the 12-week supplementation with GFA-918.

  6. The incidence of any abnormal hematology; hematocrit, with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; hematocrit, during the 12-week supplementation with GFA-918.

  7. The incidence of any abnormal hematology; platelet count, with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; platelet count, during the 12-week supplementation with GFA-918.

  8. The incidence of any abnormal hematology; RBC indices (mean corpuscular volume (MCV)) with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; RBC indices (mean corpuscular volume (MCV)), during the 12-week supplementation with GFA-918.

  9. The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin (MCH)), with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin (MCH), during the 12-week supplementation with GFA-918.

  10. The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin concentration (MCHC)), with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin concentration (MCHC)) during the 12-week supplementation with GFA-918.

  11. The incidence of any abnormal hematology; RBC indices (red cell distribution width (RDW)) with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal hematology; RBC indices (red cell distribution width (RDW)) during the 12-week supplementation with GFA-918.

  12. The incidence of any abnormal liver function measured: alanine aminotransferase (ALT), with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal liver function measured: alanine aminotransferase (ALT), during the 12-week supplementation with GFA-918.

  13. The incidence of any abnormal liver function measured: aspartate aminotransferase (AST), with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal liver function measured: aspartate aminotransferase (AST), during the 12-week supplementation with GFA-918.

  14. The incidence of any abnormal liver function measured: bilirubin, with GFA-918.

    Time frame: 12 weeks

    The incidence of any abnormal liver function measured: bilirubin, during the 12-week supplementation with GFA-918.

  15. The incidence of any abnormal kidney function parameters: serum creatinine, with GFA-918

    Time frame: 12 weeks

    The incidence of any abnormal kidney function parameters: serum creatinine, during the 12-week supplementation with GFA-918

  16. The incidence of any abnormal kidney function parameters: estimated glomerular filtration rate (eGFR), with GFA-918

    Time frame: 12 weeks

    The incidence of any abnormal kidney function parameters: estimated glomerular filtration rate (eGFR), during the 12-week supplementation with GFA-918

  17. The incidence of any abnormal kidney function parameters: electrolytes (Na, K, Cl), with GFA-918

    Time frame: 12 weeks

    The incidence of any abnormal kidney function parameters: electrolytes (Na, K, Cl), during the 12-week supplementation with GFA-918

  18. The incidence of any abnormal urinalysis measurements: colour

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: colour, during the 12-week supplementation with GFA-918.

  19. The incidence of any abnormal urinalysis measurements: appearance

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: appearance, during the 12-week supplementation with GFA-918.

  20. The incidence of any abnormal urinalysis measurements: specific gravity

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: specific gravity, during the 12-week supplementation with GFA-918.

  21. The incidence of any abnormal urinalysis measurements: pH

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: pH, during the 12-week supplementation with GFA-918.

  22. The incidence of any abnormal urinalysis measurements: presence of protein

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: presence of protein, during the 12-week supplementation with GFA-918.

  23. The incidence of any abnormal urinalysis measurements: glucose

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: glucose, during the 12-week supplementation with GFA-918.

  24. The incidence of any abnormal urinalysis measurements: ketones

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: ketones, during the 12-week supplementation with GFA-918.

  25. The incidence of any abnormal urinalysis measurements: blood

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: blood, during the 12-week supplementation with GFA-918.

  26. The incidence of any abnormal urinalysis measurements: nitrites

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: nitrites, during the 12-week supplementation with GFA-918.

  27. The incidence of any abnormal urinalysis measurements: leucocyte esterase

    Time frame: 12 weeks

    The incidence of any abnormal urinalysis measurements: leucocyte esterase, during the 12-week supplementation with GFA-918.

  28. The incidence of adverse events or abnormal safety outcomes during the follow up period, week 12 to week 14

    Time frame: 14 weeks

    The incidence of adverse events or abnormal safety outcomes during the follow up period, week 12 to week 14

Sponsors and collaborators

Lead sponsor

BIO-CAT Microbials, LLC

Industry

Collaborators

  • KGK Science Inc.

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Effect of GFA-918 on Serum Triglyceride Levels in Individuals With Elevated Serum Triglyceride

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Feb 15, 2021
Registry last updated
Dec 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.